With the title page of 2012 opened, investors are eagerly looking forward to the pharmaceutical sector to reverse the downward decline in 2011, to bring more surprises.China pacifier thermometer manufacturer Industry experts believe that the domestic pharmaceutical industry in 2012, even if faced with more complex domestic and international economic and policy environment, but can still achieve China basal thermometer a rapid growth period. Growth impetus came mainly from consumption in an aging population growing, slow-growing number of patients as well as universal health care ever-increasing ability to pay.
Can not be avoided, China waterproof thermometer the pharmaceutical industry is extremely sensitive to the policy, the policy level this year, there are still many uncertainties challenge. Brokers generally agreed that the policy fog shrouded, China fever thermometer manufacturer the pharmaceutical industry, but not smooth bright future for the pharmaceutical sector in 2012 was generally cautious optimism. From the hot market, policy uncertainty is relatively small medical device and medical services, intensity of competition in the market relatively small biological products, and benefit from the sink and cost reduction requirements and other sub-sectors of Chinese medicine more promising.
Policy into the fog period
Widely believed, this year's macro-economic face of economic growth in the pharmaceutical somewhat unfavorable. The current debt crisis in European countries is difficult to extricate themselves for the global economy cast a strong shadow. The global economic downturn or compression will result in some countries medical costs, China baby thermometer manufacturer which will be RMB appreciation and the anti-dumping and other factors affecting the drug this year, China's export situation.
At the policy level, as uncertainty increases, the pharmaceutical industry this year will no longer be simply a "honeymoon period", but "fog period."China wrist blood pressure monitor Insiders pointed out that with 850 billion yuan of new investment was announced over medical reform, medical reform into the future growth rate may slow down, or will this impact to some extent, economic growth this year medicine.
At the same time, the Government's reform of Medicare payment reflects the warming of cost control. Shanghai Medicare fee charged to prove that the implementation of measures on the rise in medical costs has played a significant role in curbing, announced the beginning of the end state in 40 cities nationwide pilot Medicare payment reform. Chen Guodong, senior pharmaceutical industry analyst pointed out that this will become the trend that control health care costs, Medicare expenditures are expected to decline this year. However, as the overall balance of health insurance is still high, and control costs are too strict may lead to personal pay has risen, so the short term, their efforts to promote or not.
Another public hospital reform is clearly affected the performance of the pharmaceutical industry this year, an important factor, but the reform of public hospitals, which still holds partly concealed. Shanghai New Century Credit Rating Company Cao Ming, general manager of public finance ratings, said the reform of public hospitals, the pattern of the impact of pharmaceutical industry is essential, but the current reform process has not been involved in the operational mechanism of public hospitals and public hospital reform has been no clear roadmap, the reform of public hospitals this year will have a substantive action. And now you can see is that countries are increasing investment in the county hospital, basic medical market expansion positive development of the industry.
Provincial policy-oriented pharmaceutical bidding the same concern, is widely considered the short term the biggest factor affecting the industry growth rate. Securities, research report, this non-tender market-based medicine will be more intensive, while the provinces are expected to continue bidding policy guidance will be quite different, types of prescription drugs will soon begin shuffling, a large number of competing products, generic drugs may be face greater price pressure. Industry analysts believe that with the expected implementation of the uniform pricing policy, considerable controversy over the bidding policy may change, thus changing the current market-based medicine embarrassment.
In addition, this year drug price reduction policy will continue. TX Irving pharmaceutical industry analyst Xiao Peng believes that the main focus of this year's fight against drug prices artificially high drug prices, and shortage of drugs for rare diseases, national policies will be introduced to protect their production. On the other hand, restricting the use of antibiotics, the impact of the policy will continue to deepen this year, "management approach clinical use of antibiotics," the official draft has not yet been out, the possibility still exists of its strict, which will market short-term antibiotic difficult to restore, on the sub-sectors of medicine will adversely affect overall performance, and increase the differentiation of varieties of antibiotics.